These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22375487)

  • 21. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
    Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
    Jones T
    Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
    Keitel WA; Atmar RL
    Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethical considerations for NIH funded highly transmissible H5N1.
    Salhanick M
    Pharos Alpha Omega Alpha Honor Med Soc; 2013; 76(1):6-9. PubMed ID: 23444692
    [No Abstract]   [Full Text] [Related]  

  • 27. Pre- or post-pandemic influenza vaccine?
    Osterhaus AD
    Vaccine; 2007 Jun; 25(27):4983-4. PubMed ID: 17555851
    [No Abstract]   [Full Text] [Related]  

  • 28. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
    Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
    Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.
    Leroux-Roels I; Van der Wielen M; Kafeja F; Vandermeulen C; Lazarus R; Snape MD; John T; Carre C; Nougarede N; Pepin S; Leroux-Roels G; Hoppenbrouwers K; Pollard AJ; Van Damme P
    Vaccine; 2009 Nov; 27(49):6918-25. PubMed ID: 19761837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
    Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine preparedness--are we ready for the next influenza pandemic?
    Wright PF
    N Engl J Med; 2008 Jun; 358(24):2540-3. PubMed ID: 18550873
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial.
    Dikow R; Eckerle I; Ksoll-Rudek D; Hampel H; Schwenger V; Zeier M; Schnitzler P; Sommerer C
    Am J Kidney Dis; 2011 May; 57(5):716-23. PubMed ID: 21349617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current cell-based influenza vaccine production technology as pandemic contingency.
    Ng SK
    Hum Vaccin Immunother; 2012 Feb; 8(2):267-71. PubMed ID: 22426381
    [No Abstract]   [Full Text] [Related]  

  • 35. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
    Girard MP; Katz J; Pervikov Y; Palkonyay L; Kieny MP
    Vaccine; 2010 Oct; 28(42):6811-20. PubMed ID: 20659520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lab flu may not aid vaccines.
    Butler D
    Nature; 2012 Feb; 482(7384):142-3. PubMed ID: 22318581
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use.
    Keating GM; Plosker GL; Lyseng-Williamson KA
    BioDrugs; 2012 Dec; 26(6):425-30. PubMed ID: 23106407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WHO wades into row over sharing of H5N1 flu research.
    Roehr B
    BMJ; 2012 Jan; 344():e30. PubMed ID: 22217637
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.